ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "pain"

  • Abstract Number: LB12 • ACR Convergence 2025

    Randomized, Double-Blind, Placebo-Controlled Phase IIa Trial of an Innovative Intra-Articular Apoptotic Cell Therapy in Knee Osteoarthritis (OA): 3-Month Positive Outcomes and Identification of Responder Population (NCT06233474)

    Philip Conaghan1, Bernt Husøy2, Cecilie Rovsing3, Sidsel L Boll4, Liliana Groppa5, Amir Oron6, Asger Bihlet7, Ali Mobasheri8, Tobias Winkler9, Dror Mevorach10, Einat Galamidi11, Lital Weinfeld-Bergman12, Lior Binder12 and Oren Hershkovitz11, 1University of Leeds, Leeds, United Kingdom, 2Sanos Clinic, Herlev, Denmark, 3Sanos Clinic, Gandrup, Denmark, 4Sanos Clinic, Vejle, Denmark, 5T. Mosneaga Republican Clinical Hospital, Chisinau, Moldova, 6Kaplan MC, Rehovot, Israel, 7NBCD A/S, Soeborg, Denmark, 8University of Oulu, Oulu, Finland, 9Charité - Universitätsmedizin Berlin, Berlin, Germany, 10Hadassah-University Hospital, Jerusalem, Israel, 11Enlivex Therapeutics, Ness Ziona, Israel, 12Enlivex Therapeutics, Nes Ziona, Israel

    Background/Purpose: OA is a prevalent disabling disease growing globally due to aging populations and rising obesity. In primary OA, the effects of joint tissue damage accumulate with age,…
  • Abstract Number: LB03 • ACR Convergence 2025

    Transcutaneous Electrical Nerve Stimulation Effectively Reduces Pain in Fibromyalgia: A Pragmatic Cluster-Randomized Trial Embedded in Physical Therapy Practice

    Leslie Crofford1, Dana Dailey2, Barbara Van Gorp2, Carol Vance2, Andrew Post3, Ruth Chimenti2, Ezgi Yarasir2, Elizabeth Johnson1, Kari Vance2, Bridget Zimmerman2, Fangfang Jiang2, David-Erick Lafontant2, Maxine Koepp2, Dixie Ecklund2, Emine Bayman2 and Kathleen Sluka2, 1Vanderbilt University Medical Center, Nashville, Tennessee, 2University of Iowa, Iowa City, Iowa, 3Grand Valley State University, Grand Rapids, Michigan

    Background/Purpose: Fibromyalgia (FM) is characterized by chronic widespread pain that is often exacerbated by movement. FM is associated with enhanced central pain transmission, while transcutaneous…
  • Abstract Number: 2261 • ACR Convergence 2025

    Palindromic Rheumatism and Predictors of Progression to Rheumatoid Arthritis: Experience from a Tertiary Care Center in Northern India

    Sryla Punjadath1, Venkatesh Srinivasa Pai1, Prativa Priyadarshani Sethi1, ritu sangwan2, Abhishek Rai3 and Ravi Kant1, 1All India Institute of Medical Sciences, Rishikesh, Rishikesh, Uttarakhand, India, 2AIIMS ,Rishikesh, Rishikesh, Uttarakhand, India, 3AIIMS ,RISHIKESH, Bhilai, Chhattisgarh, India

    Background/Purpose: Palindromic Rheumatism (PR) is recognized as a clinical syndrome of intermittent episodes of pain, swelling, and erythema in and around joints, which are severe…
  • Abstract Number: 1804 • ACR Convergence 2025

    Pharmacology of LEVI-04, a novel treatment for OA

    Simon Westbrook1 and Kerry af Forselles2, 1Levicept Ltd, Sandwich, United Kingdom, 2Levicept, Sandwich, United Kingdom

    Background/Purpose: LEVI-04 is a novel fusion protein comprising the extracellular domain of p75 neurotrophin receptor (p75NTR) coupled to IgG1 Fc, being developed for the treatment…
  • Abstract Number: 1380 • ACR Convergence 2025

    Phenotyping Neuropathic Pain in Sjögren’s Disease: A Cluster-Based Approach

    Beatrice Dei1, Stefano Donati1, Gaetano La Rocca2, Giovanni Fulvio1, Federico Fattorini1, Antonello Sulis1, Michele Moretti1, Elena Elefante1, Francesco Ferro3, Giulia Ricci4, Marta Mosca5 and Chiara Baldini5, 1Rheumatology Unit, University of Pisa, Pisa, Toscana, Italy, 2University of Pisa, Rheumatology Unit, Pisa, Pisa, Italy, 3Clinical and Experimental Medicine Department, Azienda Ospedaliero-Universitaria Pisana, Pisa, Pisa, Italy, 4Neurology Unit, University of Pisa, Pisa, Toscana, Italy, 5University of Pisa, Pisa, Pisa, Italy

    Background/Purpose: Neuropathic pain (NeP) is increasingly recognized as a relevant symptom domain in primary Sjögren’s disease (SjD), contributing to the disease burden beyond glandular involvement.…
  • Abstract Number: 1234 • ACR Convergence 2025

    Serum Antibodies Against Glial Fibrillary Acidic Protein in Fibromyalgia: A Proof-of-Concept Study

    Felipe Massó1, Laura Aline Martinez-Martinez2, Luis M Amezcua-Guerra3, Francisco Mercado4, Angélica Almanza5 and Manuel Martínez-Lavín1, 1Instituto Nacional de Cardiologia Ignacio Chavez, Mexico city, Mexico, 2Rheumatology Department at National Institute of Cardiology Ignacio Chávez, Mexico City, Federal District, Mexico, 3Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico, Mexico city, 4Instituto Nacional de Psiquiatría Ramón del la Fuente Muñiz, Mexico city, Mexico, 5Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz, Mexico city, Mexico

    Background/Purpose: Fibromyalgia (FM) is a stress-related disorder in which dorsal root ganglia (DRG) may play a pivotal pathogenetic role. DRG exhibit unique stress-induced, pro-algesic physio-anatomy,…
  • Abstract Number: 1027 • ACR Convergence 2025

    GLP-1 Receptor Agonists to Facilitate Weight Loss and Improve Disease Activity, Pain and Function in Patients With Rheumatic and Musculoskeletal Disease: Real-World Evidence From the Rheumatology Informatics System for Effectiveness (RISE) Registry

    Nick McCormick1, Jingyi Zhang2, Emily Holladay2, Fenglong Xie3 and Jeffrey Curtis4, 1Auburn University, Auburn, AL, 2University of Alabama at Birmingham, Birmingham, AL, 3The University of Alabama at Birmingham, Birmingham, AL, 4Foundation for Advancing Science, Technology, Education and Research, Birmingham, AL

    Background/Purpose: Glucagon-like peptide-1 receptor agonists (GLP-1 RA) such as semaglutide (SEM; GLP-1) and tirzepatide (TIR; GIP/GLP-1), were initially approved for type 2 diabetes management but…
  • Abstract Number: 0442 • ACR Convergence 2025

    Beyond the Joints: The Impact of Non-Articular Pain on Patient-Reported Function in a Longitudinal Real-World Early RA Cohort

    Charis Meng1, Marie-France Valois2, Caci Julia3, Yvonne Lee4, Bindee Kuriya5, Gilles Boire6, Hugues Allard-Chamard7, Carol Hitchon8, Louis Bessette9, Glen Hazlewood10, Carter Thorne11, Susan J. Bartlett12, Janet Pope13 and Vivian Bykerk1, 1Hospital for Special Surgery, New York, NY, 2McGill University, Pointe-Claire, QC, Canada, 3Hospital for Special Surgery, New York, 4Northwestern University, Chicago, IL, 5Mount Sinai Health, Toronto, Canada, 6Retired, Sherbrooke, QC, Canada, 7Université de Sherbrooke, Sherbrooke, Canada, 8University of Manitoba, Winnepeg, Canada, 9Centre de l'Ostéoporose et de Rhumatologie de Québec, Quebec, QC, Canada, 10University of Calgary, Calgary, AB, Canada, 11Southlake Regional Health Centre, Newmarket, ON, Canada, 12McGill University, Beaconsfield, QC, Canada, 13University of Western Ontario, London, ON, Canada

    Background/Purpose: A third of patients with early (e)RA report pain outside the joint or non-articular pain (NAP) despite RA treatment(1). NAP, both regional and widespread,…
  • Abstract Number: 2120 • ACR Convergence 2025

    Analyzing Gender and Racial Disparities in Paget’s Disease of Bone: A Large-Scale Observational Study

    Kinga Grzybowski1, Ahmer Khan2 and Arthur Lau3, 1Jefferson Einstein Montgomery Hospital, Maspeth, NY, 2Jefferson Einstein Philadelphia Hospital, Philadelphia, 3Jefferson Einstein Hospital, Maple Glen, PA

    Background/Purpose: Osteitis deformans, commonly referred to as Paget’s Disease of the Bone (PDB), affects adults over the age of 55, mainly of European descent and…
  • Abstract Number: 1800 • ACR Convergence 2025

    The Role of Nociceptor-Expressed Piezo2 in Nervous System Immune Cell Infiltration in a Mouse Model of Osteoarthritis

    Natalie Adamczyk1, Terese Geraghty2, Shingo Ishihara3, alia obeidat2, Jun Li2, Anne-Marie Malfait2 and Rachel Miller1, 1Rush University Medical Center, Chicago, IL, 2Rush University Medical Center, Chicago, 3Rush University, Chicago

    Background/Purpose: Osteoarthritis is one of the leading causes of chronic pain and disability worldwide with 500 million people affected. We have previously reported that nociceptor-conditional…
  • Abstract Number: 1298 • ACR Convergence 2025

    Identifying Psychosocial Profiles in Youth with Chronic Musculoskeletal Pain: A K-Means Clustering Analysis of Resilience Subgroups

    Sabrina Gmuca1, Jan Leonard2, Alexis Z. Tomlinson2, Mackenzie McGill2, Nellie Butler2, Rui Xiao3, Peter F. Cronholm3, Tonya M. Palermo4, Jami F. Young5, Abby R. Rosenberg6 and Pamela Weiss7, 1Children's Hospital of Philadelphia; University of Pennsylvania, Philadelphia, PA, 2Children's Hospital of Philadelphia, Philadelphia, 3University of Pennsylvania, Philadelphia, PA, 4University of Washington School of Medicine; Seattle Children’s Research Institute, Seattle, 5Children's Hospital of Philadelphia; University of Pennsylvania, Philadelphia, 6Dana-Farber Cancer Institute; Boston Children’s Hospital; Harvard Medical School, Boston, 7Childrens Hospital of Philadelphia, Philadelphia, PA

    Background/Purpose: Psychological resilience is low among youth with chronic musculoskeletal pain (CMP) at baseline. We aimed to explore resilience profiles among youth with CMP during…
  • Abstract Number: 1235 • ACR Convergence 2025

    Demystifying Pain in patients with Lupus: How much is it Lupus and How much is it Other Stuff?

    Meenakshi Jolly, Rush University, Chicago

    Background/Purpose: Pain in patients with Systemic Lupus Erythematosus (SLE) is not well understood. There is role of active disease in pain (e.g. arthritis, serositis) also…
  • Abstract Number: 1021 • ACR Convergence 2025

    Recent Trends in Cannabis Use Among Individuals with Rheumatic Diseases

    Kristin Wipfler1 and Kaleb Michaud2, 1FORWARD, The National Databank for Rheumatic Diseases, Omaha, NE, 2University of Nebraska Medical Center, Omaha, NE

    Background/Purpose: Cannabis use has increased substantially in the general population over the past decade, driven by changing legal landscapes and expanding public interest in its…
  • Abstract Number: 0440 • ACR Convergence 2025

    The Painful Truth: Non-Articular Pain’s Impact on Rheumatoid Arthritis Assessment after Initiating a new DMARD for Active Disease

    Charis Meng1, Jing Song2, Lutfiyya muhammad3, Caci Julia4, Tuhina Neogi5, Marcy Bolster6, Wendy Marder7, Clifton Bingham8 and Yvonne Lee9, 1Hospital for Special Surgery, New York, NY, 2Northwestern University Feinberg School of Medicine, Worthington, MN, 3Northwestern University Feinberg School of Medicine, Chicago, IL, 4Hospital for Special Surgery, New York, 5Boston University School of Medicine, Boston, MA, 6Massachusetts General Hospital, Concord, MA, 7University of Michigan, Ann Arbor, MI, 8Johns Hopkins University, Baltimore, MD, 9Northwestern University, Chicago, IL

    Background/Purpose: RA-related pain is typically thought of as pain in the joints. However, non-articular pain (NAP) is also common, persisting in 1/3 of patients with…
  • Abstract Number: 2112 • ACR Convergence 2025

    Which drugs are associated with the development of osteonecrosis of the jaw? clinical and epidemiological analysis of a cohort of patients diagnosed with osteonecrosis of the jaw.

    Esther Monleon Acosta1, Alicia Pérez González2, José Andrés Rodríguez Fernández2, Pedro José Manuel Hernández2, María del Rosario Oliva Ruiz2, José María Andreu Ubero2, Paloma Valentina Castillo Dayer2, Gloria Albaladejo Paredes3, Carlos Fernández Díaz4, Angela Egea Fuentes2, Montserrat Fernández Salamanca2 and Vicente Cogolludo Campillo5, 1Hospital Santa Lucia, Cartagena, Spain, 2Hospital General Universitario Santa Lucia, Cartagena, Spain, 3Hospital General Universitario Santa Lucía, CARTAGENA, Spain, 4H.U. Santa Lucia, Murcia, Spain, 5Hospital General Universitario Santa Lucia, Santa Lucia, Cartage, Spain

    Background/Purpose: Osteonecrosis of the jaw (ONJ) is defined as avascular necrosis of bone located in the maxillofacial region with the presence of exposed bone or…
  • 1
  • 2
  • 3
  • …
  • 44
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology